NEW: 2022 Billing for COVID-19 Vaccine and Monoclonal Antibody Products for Medicare Advantage Plan Patients

Published 02/23/2022

Claims for COVID-19 vaccinations or monoclonal antibody treatment provided to patients enrolled in Medicare Advantage (MA) plans on or after January 1, 2022, must be submitted to the patient’s Medicare Advantage Plan.

Original Medicare will no longer make payment for these services provided to a MA Plan patient. Questions about Original Medicare nonpayment for these services as of January 1, 2022, direction on billing the MA Plan or MA Plan payment amounts must be directed to the individual patient’s MA Plan. Palmetto GBA cannot provide direction on MA Plan billing or policies. 

COVID 19 vaccines and monoclonal antibody treatments provided to MA plan patients prior to January 1, 2022, continue to be billed to Original Medicare. CMS MLN Connects: Thursday, December 16, 2021


Was this article helpful?

Palmetto GBA Web Chat

Sounds: OnSave Transcript
Please answer the questions below. Additional fields may appear based on previous answers. Fields with a red asterisk (*) are required.
Your InformationClear
1()-x
Inquiry InformationClear
Select your stateClear
Select your stateClear
Provider InformationClear
Patient InformationClear
Patient Name must exactly match the information submitted on the claim, including suffix if applicable.
//
Appeal InformationClear
//
//
Claim InformationClear
//
//
Denial InformationClear
//
//
Rejection InformationClear
DDE InformationClear
Restore InformationClear
//
Application InformationClear
Product InformationClear
OtherClear
Additional InformationClear

Are you sure you want to end your chat?

Keep ChattingClose ChatSave Transcript & Close

Webchat

Our dedicated webchat representatives are online to assist you with your general inquiries, provider enrollment, EDI, eServices and more in real-time.